Albendazole and Mebendazole as an Alternative Therapeutic Agent for Adult Giardiasis

We examined the therapeutic effects of albendazole. metronidazole and mebenazole 183 patients with giardiasis in Tehran Province. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days) or mebendazole (200 mg, 2 times a day...

Full description

Saved in:
Bibliographic Details
Published in:Biosciences, biotechnology research Asia biotechnology research Asia, 2016-06, Vol.13 (2), p.961-965
Main Authors: Shokouh, Seyyed Javad Hosseini, Ahmadi, Mossa
Format: Article
Language:English
Subjects:
Albendazole
Chemical compounds
Clinical trials
Cysts
Demographics
Family medical history
Giardia
Giardiasis
Mebendazole
Metronidazole
Parasites
Patients
Pediatrics
Pharmacology
Secondary school students
Secondary schools
Side effects
Statistical analysis
Trophozoites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page 965
container_issue 2
container_start_page 961
container_title Biosciences, biotechnology research Asia
container_volume 13
creator Shokouh, Seyyed Javad Hosseini
Ahmadi, Mossa
description We examined the therapeutic effects of albendazole. metronidazole and mebenazole 183 patients with giardiasis in Tehran Province. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days) or mebendazole (200 mg, 2 times a day for 5 days) . Demographic data of the patients, results of stool exa­mination for Giardia (cyst or trophozoites ) before and after treatment, and drug side-effects were recorded. The final results showed that albendazole (93%) and mebendazole ( 89% ) and metronidazole (95.5%) have similar therapeutic effects on giardiasis . Patients in the albendazole group(19.7%) had fewer side-effects compared with metronidazole (39%) & mebendazole groups (27%) . This difference is statistically significant (p < 0.01). We offer the albendazole as a grug of choice of giardiasis.
doi_str_mv 10.13005/bbra/2121
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_journals_2097629798</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2097629798</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1691-12e33dcfc5978fe50030397e4efbe0c56acbcf2c8c11f301cd88f955708cb7893</originalsourceid><addsrcrecordid>eNpNkFFLwzAUhYMoOOZe_AUB34S6m2RpkscydBMmvtTnkKY32lHbmbSC_no754NPh3s4XM75CLlmcMcEgFxWVXRLzjg7IzO-knnGc-DnZAZGiYxNziVZpLQHAA4GFGMzUhZthV3tvvsWqetq-oT_7jRZtGgHjJ0bmk-k5RtGd8BxaDwtXrEbaOgjLeqxHeimcbFuXGrSFbkIrk24-NM5eXm4L9fbbPe8eVwXu8yz3LCpEQpR--ClUTqgBBAgjMIVhgrBy9z5ygfutWcsCGC-1joYKRVoXyltxJzcnP4eYv8xYhrsvh-nqm2y00CVc6OMnlK3p5SPfUoRgz3E5t3FL8vA_oKzR3D2CE78AIq8YF0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2097629798</pqid></control><display><type>article</type><title>Albendazole and Mebendazole as an Alternative Therapeutic Agent for Adult Giardiasis</title><source>Publicly Available Content Database</source><creator>Shokouh, Seyyed Javad Hosseini ; Ahmadi, Mossa</creator><creatorcontrib>Shokouh, Seyyed Javad Hosseini ; Ahmadi, Mossa</creatorcontrib><description>We examined the therapeutic effects of albendazole. metronidazole and mebenazole 183 patients with giardiasis in Tehran Province. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days) or mebendazole (200 mg, 2 times a day for 5 days) . Demographic data of the patients, results of stool exa­mination for Giardia (cyst or trophozoites ) before and after treatment, and drug side-effects were recorded. The final results showed that albendazole (93%) and mebendazole ( 89% ) and metronidazole (95.5%) have similar therapeutic effects on giardiasis . Patients in the albendazole group(19.7%) had fewer side-effects compared with metronidazole (39%) &amp; mebendazole groups (27%) . This difference is statistically significant (p &lt; 0.01). We offer the albendazole as a grug of choice of giardiasis.</description><identifier>ISSN: 0973-1245</identifier><identifier>EISSN: 2456-2602</identifier><identifier>DOI: 10.13005/bbra/2121</identifier><language>eng</language><publisher>Bhopal: Biosciences Biotechnology Research Asia</publisher><subject>Albendazole ; Chemical compounds ; Clinical trials ; Cysts ; Demographics ; Family medical history ; Giardia ; Giardiasis ; Mebendazole ; Metronidazole ; Parasites ; Patients ; Pediatrics ; Pharmacology ; Secondary school students ; Secondary schools ; Side effects ; Statistical analysis ; Trophozoites</subject><ispartof>Biosciences, biotechnology research Asia, 2016-06, Vol.13 (2), p.961-965</ispartof><rights>2018. This work is licensed under http://creativecommons.org/licenses/by-nc-sa/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2097629798/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2097629798?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,44590,74998</link.rule.ids></links><search><creatorcontrib>Shokouh, Seyyed Javad Hosseini</creatorcontrib><creatorcontrib>Ahmadi, Mossa</creatorcontrib><title>Albendazole and Mebendazole as an Alternative Therapeutic Agent for Adult Giardiasis</title><title>Biosciences, biotechnology research Asia</title><description>We examined the therapeutic effects of albendazole. metronidazole and mebenazole 183 patients with giardiasis in Tehran Province. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days) or mebendazole (200 mg, 2 times a day for 5 days) . Demographic data of the patients, results of stool exa­mination for Giardia (cyst or trophozoites ) before and after treatment, and drug side-effects were recorded. The final results showed that albendazole (93%) and mebendazole ( 89% ) and metronidazole (95.5%) have similar therapeutic effects on giardiasis . Patients in the albendazole group(19.7%) had fewer side-effects compared with metronidazole (39%) &amp; mebendazole groups (27%) . This difference is statistically significant (p &lt; 0.01). We offer the albendazole as a grug of choice of giardiasis.</description><subject>Albendazole</subject><subject>Chemical compounds</subject><subject>Clinical trials</subject><subject>Cysts</subject><subject>Demographics</subject><subject>Family medical history</subject><subject>Giardia</subject><subject>Giardiasis</subject><subject>Mebendazole</subject><subject>Metronidazole</subject><subject>Parasites</subject><subject>Patients</subject><subject>Pediatrics</subject><subject>Pharmacology</subject><subject>Secondary school students</subject><subject>Secondary schools</subject><subject>Side effects</subject><subject>Statistical analysis</subject><subject>Trophozoites</subject><issn>0973-1245</issn><issn>2456-2602</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNpNkFFLwzAUhYMoOOZe_AUB34S6m2RpkscydBMmvtTnkKY32lHbmbSC_no754NPh3s4XM75CLlmcMcEgFxWVXRLzjg7IzO-knnGc-DnZAZGiYxNziVZpLQHAA4GFGMzUhZthV3tvvsWqetq-oT_7jRZtGgHjJ0bmk-k5RtGd8BxaDwtXrEbaOgjLeqxHeimcbFuXGrSFbkIrk24-NM5eXm4L9fbbPe8eVwXu8yz3LCpEQpR--ClUTqgBBAgjMIVhgrBy9z5ygfutWcsCGC-1joYKRVoXyltxJzcnP4eYv8xYhrsvh-nqm2y00CVc6OMnlK3p5SPfUoRgz3E5t3FL8vA_oKzR3D2CE78AIq8YF0</recordid><startdate>20160601</startdate><enddate>20160601</enddate><creator>Shokouh, Seyyed Javad Hosseini</creator><creator>Ahmadi, Mossa</creator><general>Biosciences Biotechnology Research Asia</general><scope>AAYXX</scope><scope>CITATION</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M7P</scope><scope>P5Z</scope><scope>P62</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20160601</creationdate><title>Albendazole and Mebendazole as an Alternative Therapeutic Agent for Adult Giardiasis</title><author>Shokouh, Seyyed Javad Hosseini ; Ahmadi, Mossa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1691-12e33dcfc5978fe50030397e4efbe0c56acbcf2c8c11f301cd88f955708cb7893</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Albendazole</topic><topic>Chemical compounds</topic><topic>Clinical trials</topic><topic>Cysts</topic><topic>Demographics</topic><topic>Family medical history</topic><topic>Giardia</topic><topic>Giardiasis</topic><topic>Mebendazole</topic><topic>Metronidazole</topic><topic>Parasites</topic><topic>Patients</topic><topic>Pediatrics</topic><topic>Pharmacology</topic><topic>Secondary school students</topic><topic>Secondary schools</topic><topic>Side effects</topic><topic>Statistical analysis</topic><topic>Trophozoites</topic><toplevel>online_resources</toplevel><creatorcontrib>Shokouh, Seyyed Javad Hosseini</creatorcontrib><creatorcontrib>Ahmadi, Mossa</creatorcontrib><collection>CrossRef</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Biological Science Journals</collection><collection>Advanced Technologies &amp; Aerospace Database</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>Biosciences, biotechnology research Asia</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shokouh, Seyyed Javad Hosseini</au><au>Ahmadi, Mossa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Albendazole and Mebendazole as an Alternative Therapeutic Agent for Adult Giardiasis</atitle><jtitle>Biosciences, biotechnology research Asia</jtitle><date>2016-06-01</date><risdate>2016</risdate><volume>13</volume><issue>2</issue><spage>961</spage><epage>965</epage><pages>961-965</pages><issn>0973-1245</issn><eissn>2456-2602</eissn><abstract>We examined the therapeutic effects of albendazole. metronidazole and mebenazole 183 patients with giardiasis in Tehran Province. Patients were randomized to receive albendazole (400 mg, once daily for 5 days) or metronidazole (250 mg, 3 times a day for 5 days) or mebendazole (200 mg, 2 times a day for 5 days) . Demographic data of the patients, results of stool exa­mination for Giardia (cyst or trophozoites ) before and after treatment, and drug side-effects were recorded. The final results showed that albendazole (93%) and mebendazole ( 89% ) and metronidazole (95.5%) have similar therapeutic effects on giardiasis . Patients in the albendazole group(19.7%) had fewer side-effects compared with metronidazole (39%) &amp; mebendazole groups (27%) . This difference is statistically significant (p &lt; 0.01). We offer the albendazole as a grug of choice of giardiasis.</abstract><cop>Bhopal</cop><pub>Biosciences Biotechnology Research Asia</pub><doi>10.13005/bbra/2121</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-1245
ispartof Biosciences, biotechnology research Asia, 2016-06, Vol.13 (2), p.961-965
issn 0973-1245
2456-2602
language eng
recordid cdi_proquest_journals_2097629798
source Publicly Available Content Database
subjects Albendazole
Chemical compounds
Clinical trials
Cysts
Demographics
Family medical history
Giardia
Giardiasis
Mebendazole
Metronidazole
Parasites
Patients
Pediatrics
Pharmacology
Secondary school students
Secondary schools
Side effects
Statistical analysis
Trophozoites
title Albendazole and Mebendazole as an Alternative Therapeutic Agent for Adult Giardiasis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T15%3A12%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Albendazole%20and%20Mebendazole%20as%20an%20Alternative%20Therapeutic%20Agent%20for%20Adult%20Giardiasis&rft.jtitle=Biosciences,%20biotechnology%20research%20Asia&rft.au=Shokouh,%20Seyyed%20Javad%20Hosseini&rft.date=2016-06-01&rft.volume=13&rft.issue=2&rft.spage=961&rft.epage=965&rft.pages=961-965&rft.issn=0973-1245&rft.eissn=2456-2602&rft_id=info:doi/10.13005/bbra/2121&rft_dat=%3Cproquest_cross%3E2097629798%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1691-12e33dcfc5978fe50030397e4efbe0c56acbcf2c8c11f301cd88f955708cb7893%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2097629798&rft_id=info:pmid/&rfr_iscdi=true